CRITICAL REVIEW ON VIDARIKAND (PUERARIA TUBEROSA DC.) -AN AYURVEDIC HERB

Background: Vidarikand is the one of the most important drug which has broadly described in detail in all the textbook of Ayurveda. It is commonly known as Indian kudzu which is a perennial climber with woody tuberculated stem with large tuberous roots. Generally all the Nighantus are mention its various properties. It is used in variety of formulation mention in Ayurvedic Samhita for the different-different purpose and treatment of diseases. There are so many researches were done on Vidarikand on range of diseases and its property. Aims and Objects: This paper trying to elaborate, evaluate and discuss the medicinal property, therapeutic effects of Vidarikanda in various diseases including new emerging problems. Material and Method: The text book of Ayurveda, its commentaries and text book of modern medicine along with various clinical studies published in index journal have been review thoroughly. Result and Discussion: Vidarikanda has Madhur Rasa,Shita Veerya and Guru, Snigdh Guna and it pacify Vata, Pitta and Rakta dosha and having Brihani, Vrashya, Jivniya, Rasayan, Stanya, Shukral, Balya property mention in Ayurvedic text due to these excellent property its field of use is highly amplified for cure diseases. Its formulations are highly used in Jwara, Raktapitta, Rajayakshma, Apasmar, Kshatksina, Kasa, Vatavyadhi, Vatarakta, Klevya and many more diseases. It is also mentioned in Balavarna vardhak and Vranaropak formulation. It is good in Immunomodulting, Antioxidant, Galactogogue, Cardiotonic, Aphrodisiac, Rejuvenation, Nootropic and Anti-inflammatory effect

Frequency-interleaved SDM transmission over multicore fiber for next generation short-reach optical interconnect systems

Space division multiplexing (SDM) technique is proposed to overcome the bandwidth density drives of short-reach optical transmission systems by utilizing 8-core multicore fiber (MCF). Intercore crosstalk (XT) and higher order modulation format are the most challenging impairments of SDM based optical interconnect (OI) systems. To satisfy the exponential growth of the Internet traffic a frequency interleaving scheme is applied to short-reach MCF OI transmission systems. The negative effects of spectral overlap and intercore XT is reduced by shifting channel frequencies between adjacent cores. To exploit the full potential of SDM power efficient binary phase shift keying (BPSK) modulation format and digital signal processing such as multiple input multiple output (MIMO) equalization are used

Pain outcomes in children who received intrathecal vs intravenous opioids for pain control following major urologic surgery: a retrospective review

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/115913/1/pan12781_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/115913/2/pan12781.pd

Factors influencing return to work after hip and knee replacement

Background: Return to employment is one of the key goals of joint replacement surgery in the working-age population. There is limited quantitative and qualitative research focusing on return to work after hip and knee replacement. It remains unclear why certain groups of patients are not able to achieve sufficient functional improvement to allow productive return to work while others can. Very little is known about the individual patient and employer perspectives in this regard. Aims: To review current evidence for the factors influencing employment outcomes in patients undergoing hip and knee replacement. Methods: Original articles and reviews in Medline, Embase and PsycINFO from 1987 to 2013 were included in the analysis. Results: Age, patient motivation, employment before surgery and type of job were found to be important factors in determining return to work following hip and knee replacement. Conclusions: There is a need for further qualitative work on how and why these factors influence employment outcomes. Keywords: Arthritis; joint replacement; occupational rehabilitation; qualitative

An Open Community-Driven Model For Sustainable Research Software: Sustainable Research Software Institute

Research software plays a crucial role in advancing scientific knowledge, but ensuring its sustainability, maintainability, and long-term viability is an ongoing challenge. To address these concerns, the Sustainable Research Software Institute (SRSI) Model presents a comprehensive framework designed to promote sustainable practices in the research software community. This white paper provides an in-depth overview of the SRSI Model, outlining its objectives, services, funding mechanisms, collaborations, and the significant potential impact it could have on the research software community. It explores the wide range of services offered, diverse funding sources, extensive collaboration opportunities, and the transformative influence of the SRSI Model on the research software landscapeComment: 13 pages, 1 figur

Transitioning ECP Software Technology into a Foundation for Sustainable Research Software

Research software plays a crucial role in advancing scientific knowledge, but ensuring its sustainability, maintainability, and long-term viability is an ongoing challenge. The Sustainable Research Software Institute (SRSI) Model has been designed to address the concerns, and presents a comprehensive framework designed to promote sustainable practices in the research software community. However the SRSI Model does not address the transitional requirements for the Exascale Computing Project (ECP) Software Technology (ECP-ST) focus area specifically. This white paper provides an overview and detailed description of how ECP-ST will transition into the SRSI in a compressed time frame that a) meets the needs of the ECP end-of-technical-activities deadline; and b) ensures the continuity of the sustainability efforts that are already underway.Comment: 7 pages, 1 figur

Increased respiratory symptoms following surgery in children exposed to environmental tobacco smoke

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75635/1/j.1460-9592.2003.01100.x.pd

Colocalization of different neurotransmitter transporters on synaptic vesicles is sparse except for VGLUT1 and ZnT3

Vesicular transporters (VTs) define the type of neurotransmitter that synaptic vesicles (SVs) store and release. While certain mammalian neurons release multiple transmitters, it is not clear whether the release occurs from the same or distinct vesicle pools at the synapse. Using quantitative single-vesicle imaging, we show that a vast majority of SVs in the rodent brain contain only one type of VT, indicating specificity for a single neurotransmitter. Interestingly, SVs containing dual transporters are highly diverse (27 types) but small in proportion (2% of all SVs), excluding the largest pool that carries VGLUT1 and ZnT3 (34%). Using VGLUT1-ZnT3 SVs, we demonstrate that the transporter colocalization influences the SV content and synaptic quantal size. Thus, the presence of diverse transporters on the same vesicle is bona fide, and depending on the VT types, this may act to regulate neurotransmitter type, content, and release in space and time

Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies

The closing of the last century opened a wide variety of approaches for inflammation imaging and treatment of patients with rheumatoid arthritis (RA). The introduction of biological therapies for the management of RA started a revolution in the therapeutic armamentarium with the development of several novel monoclonal antibodies (mAbs), which can be murine, chimeric, humanised and fully human antibodies. Monoclonal antibodies specifically bind to their target, which could be adhesion molecules, activation markers, antigens or receptors, to interfere with specific inflammation pathways at the molecular level, leading to immune-modulation of the underlying pathogenic process. These new generation of mAbs can also be radiolabelled by using direct or indirect method, with a variety of nuclides, depending upon the specific diagnostic application. For studying rheumatoid arthritis patients, several monoclonal antibodies and their fragments, including anti-TNF-α, anti-CD20, anti-CD3, anti-CD4 and anti-E-selectin antibody, have been radiolabelled mainly with 99mTc or 111In. Scintigraphy with these radiolabelled antibodies may offer an exciting possibility for the study of RA patients and holds two types of information: (1) it allows better staging of the disease and diagnosis of the state of activity by early detection of inflamed joints that might be difficult to assess; (2) it might provide a possibility to perform ‘evidence-based biological therapy’ of arthritis with a view to assessing whether an antibody will localise in an inflamed joint before using the same unlabelled antibody therapeutically. This might prove particularly important for the selection of patients to be treated since biological therapies can be associated with severe side-effects and are considerably expensive. This article reviews the use of radiolabelled mAbs in the study of RA with particular emphasis on the use of different radiolabelled monoclonal antibodies for therapy decision-making and follow-up